Evidence map›Paper›PMID 33125497›Full record

ArticleJAMA network open2020

Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial.

Erin L Van Blarigan, Sui Zhang, Fang-Shu Ou, Alan Venlo, Kimmie Ng, Chloe Atreya, Katherine Van Loon, Donna Niedzwiecki, Edward Giovannucci, Eric G Wolfe and 13 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 4 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Exercise Prescription in Cardio-Oncology.Journal of clinical medicine · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 16 institutions in 1 country.

Erin L Van BlariganDepartment of Epidemiology and Biostatistics, University of California, San Francisco.
Sui ZhangDana-Farber/Partners CancerCare, Boston, Massachusetts.
Fang-Shu OuAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota.
Alan VenloDepartment of Medicine, University of California, San Francisco.
Kimmie NgDana-Farber/Partners CancerCare, Boston, Massachusetts.
Chloe AtreyaDepartment of Medicine, University of California, San Francisco.
Katherine Van LoonDepartment of Medicine, University of California, San Francisco.
Donna NiedzwieckiAlliance Statistics and Data Center, Duke University, Durham, North Carolina.
Edward GiovannucciDepartment of Nutrition and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Eric G WolfeAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota.
Heinz-Josef LenzUSC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.
Federico InnocentiDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; Department of Medicine-Hematology, University of North Carolina at Chapel Hill.
Bert H O'NeilSimon Cancer Center, Indiana University School of Medicine, Indianapolis.
James E ShawVirginia Commonwealth University, Richmond.
Blase N PolitePritzker School of Medicine, The University of Chicago, Chicago, Illinois.
Howard S HochsterDepartment of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut.
James N AtkinsSoutheast Clinical Oncology Research Consortium, Winston-Salem, North Carolina.
Richard M GoldbergWest Virginia University Cancer Institute, Morgantown.
Robert J MayerDana-Farber/Partners CancerCare, Boston, Massachusetts.
Charles D BlankeSWOG Group Chair's Office, Knight Cancer Institute, Oregon Health & Science University, Portland.
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, New York, New York.
Charles S FuchsYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Jeffrey A MeyerhardtDana-Farber/Partners CancerCare, Boston, Massachusetts.
CancerCare · USUniversity of California, San Francisco · USMayo Clinic · USAlliance Data (United States) · USHarvard University · USIndiana University Health · USMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USSoutheast Clinical Oncology Research Consortium · USUniversity of Chicago · USUniversity of North Carolina at Chapel Hill · USUniversity of Southern California · USVirginia Commonwealth University · USWest Virginia University · USYale Cancer Center · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Southeast Clinical Oncology Research Consortium, Inc. (SCOR)UG1CA189858 · NCI · SOUTHEAST CLINICAL ONCOL RES CONSORTIUM · PI Judith O Hopkins, William J Irvin · 2014 to 2026
$38.8M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
Yale Cancer Center NCTN LAPSUG1CA233337 · NCI · YALE UNIVERSITY · PI ANNE C CHIANG · 2019 to 2026
$6.0M
NCATS NIH HHS UL1 TR001863NCI NIH HHS K07 CA197077NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA118553NCI NIH HHS R01 CA169141NCI NIH HHS R01 CA205406NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA180830NCI NIH HHS UG1 CA189858NCI NIH HHS UG1 CA189974NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233337NCI NIH HHS UG1 CA233373NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Importance: Diet has been associated with survival in patients with stage I to III colorectal cancer, but data on patients with metastatic colorectal cancer are limited. Objective: To examine the association between diet quality and overall survival among individuals with metastatic colorectal cancer. Design, Setting, and Participants: This was a prospective cohort study of patients with metastatic colorectal cancer who were enrolled in the Cancer and Leukemia Group B (Alliance) and Southwest Oncology Group 80405 trial between October 27, 2005, and February 29, 2012, and followed up through January 2018. Exposures: Participants completed a validated food frequency questionnaire within 4 weeks after initiation of first-line treatment for metastatic colorectal cancer. Diets were categorized according to the Alternative Healthy Eating Index (AHEI), Alternate Mediterranean Diet (AMED) score, Dietary Approaches to Stop Hypertension (DASH) score, and Western and prudent dietary patterns derived using principal component analysis. Participants were categorized into sex-specific quintiles. Main Outcomes and Measures: Multivariable hazard ratios (HRs) and 95% CIs for overall survival. Results: In this cohort study of 1284 individuals with metastatic colorectal cancer, the median age was 59 (interquartile range [IQR]: 51-68) years, median body mass index was 27.2 (IQR, 24.1-31.4), 521 (41%) were female, and 1102 (86%) were White. There were 1100 deaths during a median follow-up of 73 months (IQR, 64-87 months). We observed an inverse association between the AMED score and risk of death (HR quintile 5 vs quintile 1, 0.83; 95% CI, 0.67-1.04; P = .04 for trend), but the point estimates were not statistically significant. None of the other diet scores or patterns were associated with overall survival. Conclusions and Relevance: In this prospective analysis of patients with metastatic colorectal cancer, diet quality assessed at initiation of first-line treatment for metastatic disease was not associated with overall survival.

Indexed as

Food QualityAgedCohort StudiesColorectal NeoplasmsFemaleHumansLeukemiaMaleMedical OncologyMiddle AgedMultivariate AnalysisProspective StudiesSurveys and QuestionnairesSurvival Analysis

Identifiers

PMID33125497
PMCPMC7599454
OpenAlexW3096180069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.